Intuitive Surgical (NASDAQ:ISRG) Shares Down 0.7% on Insider Selling

Intuitive Surgical, Inc. (NASDAQ:ISRG) shares traded down 0.7% during trading on Wednesday following insider selling activity. The stock traded as low as $581.06 and last traded at $587.43. 220,386 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 1,759,780 shares. The stock had previously closed at $591.65.

Specifically, EVP Myriam Curet sold 408 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $589.75, for a total transaction of $240,618.00. Following the completion of the transaction, the executive vice president now directly owns 353 shares of the company’s stock, valued at $208,181.75. This represents a 53.61 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jamie Samath sold 269 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $590.00, for a total transaction of $158,710.00. Following the transaction, the chief financial officer now directly owns 3,282 shares of the company’s stock, valued at $1,936,380. This represents a 7.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. UBS Group increased their target price on shares of Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Mizuho upped their price target on shares of Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. Oppenheimer restated a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. Evercore ISI upped their price target on shares of Intuitive Surgical from $490.00 to $530.00 in a research note on Monday, January 27th. Finally, Raymond James raised their price objective on shares of Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Stock Performance

The company has a market capitalization of $209.12 billion, a PE ratio of 91.59, a PEG ratio of 5.67 and a beta of 1.39. The business’s 50-day moving average is $556.91 and its 200-day moving average is $516.98.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Atala Financial Inc purchased a new position in Intuitive Surgical during the 4th quarter valued at about $25,000. Berbice Capital Management LLC purchased a new position in Intuitive Surgical during the 4th quarter valued at about $26,000. BankPlus Trust Department purchased a new position in Intuitive Surgical during the 4th quarter valued at about $28,000. Godsey & Gibb Inc. raised its holdings in Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in Intuitive Surgical in the fourth quarter worth about $31,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.